Publicacións nas que colabora con Mariano Valdés Chávarri (15)

2020

  1. Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries

    American Heart Journal, Vol. 220, pp. 108-115

  2. Incidence, prognosis and predictors of heart failure after acute myocardial infarction

    REC: CardioClinics, Vol. 55, Núm. 1, pp. 8-14

  3. Incidence, prognosis and predictors of heart failure after acute myocardial infarction

    REC: CardioClinics, Vol. 55, Núm. 1, pp. 8-14

  4. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry

    European Journal of Preventive Cardiology, Vol. 27, Núm. 7, pp. 696-705

2019

  1. Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or Prasugrel

    Revista Espanola de Cardiologia, Vol. 72, Núm. 4, pp. 298-304

  2. Correction to: Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry (American Journal of Cardiovascular Drugs, (2019), 19, 4, (381-391), 10.1007/s40256-019-00339-3)

    American Journal of Cardiovascular Drugs

  3. Incidence, predictors and prognosis of new-onset cancer after hospital discharge for acute coronary syndrome

    REC: CardioClinics, Vol. 54, Núm. 3, pp. 148-156

  4. Incidence, predictors and prognosis of new-onset cancer after hospital discharge for acute coronary syndrome

    REC: CardioClinics, Vol. 54, Núm. 3, pp. 148-156

  5. Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry

    American Journal of Cardiovascular Drugs, Vol. 19, Núm. 4, pp. 381-391

  6. Renin–Angiotensin System Blockade and Risk of Heart Failure After Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study

    American Journal of Cardiovascular Drugs, Vol. 19, Núm. 5, pp. 487-495

  7. Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome

    Revista Espanola de Cardiologia, Vol. 72, Núm. 3, pp. 215-223

2018

  1. Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry

    Thrombosis Research, Vol. 167, pp. 142-148

  2. Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y12 Inhibitors in Patients With Acute Coronary Syndrome

    Revista Espanola de Cardiologia, Vol. 71, Núm. 7, pp. 538-544

  3. Differential Prognostic Impact on Mortality of Myocardial Infarction Compared With Bleeding Severity in Contemporary Acute Coronary Syndrome Patients

    Revista Espanola de Cardiologia, Vol. 71, Núm. 10, pp. 829-836

  4. Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry

    International Journal of Cardiology, Vol. 273, pp. 29-33